Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer

2001474 citationsJournal Articlebronze Open Access

Authors

John Nemunaitis

Fadlo R. Khuri · Regional Cancer Center

Ian Ganly · Texas Oncology

James C. Arseneau · University of Chicago

Marshall R. Posner · Dana-Farber Cancer Institute

Everett E. Vokes · Texas Oncology

Joseph A. Kuhn · Texas Oncology

Abstract

ONYX-015 can be safely administered via intratumoral injection to patients with recurrent/refractory SCCHN. ONYX-015 viremia is transient. Evidence of modest antitumoral activity is suggested.

Topics & Keywords

Virus-based gene therapy research CAR-T cell therapy research RNA Interference and Gene Delivery

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 19, Issue 2, pp. 289-298

DOI: 10.1200/jco.2001.19.2.289

Field-Weighted Citation Impact: 24.20